Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), also known as ITGAL, is a protein that in humans is encoded by the ITGAL gene.[5] CD11a functions in the immune system. It is involved in cellular adhesion and costimulatory signaling. It is the target of the drug efalizumab.
ITGAL gene encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed in all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling.[6]
CD11a is one of the two components, along with CD18, which form lymphocyte function-associated antigen-1.
Efalizumab acts as an immunosuppressant by binding to CD11a but was withdrawn in 2009 because it was associated with severe side effects.
CD11a has been shown to interact with ICAM-1.[7][8][9]
PDB gallery
| |
---|---|
1cqp: CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION
1dgq: NMR SOLUTION STRUCTURE OF THE INSERTED DOMAIN OF HUMAN LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1
1lfa: CD11A I-DOMAIN WITH BOUND MN++
1mjn: Crystal Structure of the intermediate affinity aL I domain mutant
1mq8: Crystal structure of alphaL I domain in complex with ICAM-1
1mq9: Crystal structure of high affinity alphaL I domain with ligand mimetic crystal contact
1mqa: Crystal structure of high affinity alphaL I domain in the absence of ligand or metal
1rd4: An allosteric inhibitor of LFA-1 bound to its I-domain
1t0p: Structural Basis of ICAM recognition by integrin alpahLbeta2 revealed in the complex structure of binding domains of ICAM-3 and alphaLbeta2 at 1.65 A
1xdd: X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution
1xdg: X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution
1xuo: X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution
1zon: CD11A I-DOMAIN WITHOUT BOUND CATION
1zoo: CD11A I-DOMAIN WITH BOUND MAGNESIUM ION
1zop: CD11A I-DOMAIN WITH BOUND MAGNESIUM ION
2ica: CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid
2o7n: CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile
|
| |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alpha |
| ||||||||||||
Beta |
| ||||||||||||
Dimers |
| ||||||||||||
see also cell surface receptor deficiencies |
![]() | This article on a gene on human chromosome 16 is a stub. You can help Wikipedia by expanding it. |